Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9Y5NX)

Drug Name

ISIS 173831 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aurora B messenger RNA (AURKB mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PHA-739358	DMGYBZI	Prostate cancer	2C82.0	Phase 2	[2]
Indirubin-3'-monoxime	DMLRQH0	Discovery agent	N.A.	Investigative	[3]
SU 6656	DMF1P6W	Discovery agent	N.A.	Investigative	[4]
6-bromoindirubin-3-oxime	DM12WYV	Discovery agent	N.A.	Investigative	[3]
7-fluoroindirubin-3-oxime	DMQD34N	Discovery agent	N.A.	Investigative	[3]
PMID21742770C1	DME3JMH	Discovery agent	N.A.	Investigative	[5]
Indirubin-3-acetoxime	DM3UR1E	Discovery agent	N.A.	Investigative	[3]
CGP-57380	DMFPOUC	Discovery agent	N.A.	Investigative	[4]
PMID20855207C25	DMNEB6J	Discovery agent	N.A.	Investigative	[6]
Indirubin-3-methoxime	DMZ5ODC	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aurora B messenger RNA (AURKB mRNA)	TT9RTBL	AURKB_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	US patent application no. 7,375,212, Modulation of Aurora B expression.
2	Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
3	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
4	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
5	A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
6	Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.